Free Trial
NASDAQ:XDNA

Kelly CRISPR & Gene Editing Technology ETF (XDNA) Price, Holdings, & News

Kelly CRISPR & Gene Editing Technology ETF logo
$7.38 0.00 (0.00%)
As of 08/18/2025

About Kelly CRISPR & Gene Editing Technology ETF (NASDAQ:XDNA)

Key Stats

Today's Range
$7.38
$7.38
50-Day Range
$7.38
$7.38
52-Week Range
$5.87
$11.83
Volume
N/A
Average Volume
3,034 shs
Market Capitalization
$2.21 million
Assets Under Management
$2.58 million
Dividend Yield
0.12%
Net Expense Ratio
0.78%
Aggregate Rating
N/A

ETF Overview

Kelly CRISPR & Gene Editing Technology ETF Expenses

TypeXDNATheme ETFsEquity ETFsNASDAQ ETFsAll ETFs
Management Fee0.78%0.57%0.56%0.54%0.53%
Other Expenses0.00%0.57%0.56%0.52%0.56%
Total Expense0.78%0.74%0.76%0.73%0.73%
Fee Waiver0.00%-0.76%-0.66%-0.50%-0.63%
Net Expense0.78%0.60%0.63%0.63%0.60%
Receive XDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kelly CRISPR & Gene Editing Technology ETF and its competitors with MarketBeat's FREE daily newsletter.

XDNA ETF News Headlines

The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”tc pixel
K-12 Genome Editing at Only $2 a Pop
See More Headlines

XDNA ETF - Frequently Asked Questions

Kelly CRISPR & Gene Editing Technology ETF's stock was trading at $7.38 at the beginning of the year. Since then, XDNA stock has increased by 0.0% and is now trading at $7.38.

Shares of XDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kelly CRISPR & Gene Editing Technology ETF investors own include Meta Platforms (META), RTX (RTX), Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Cloudflare (NET), Birkenstock (BIRK) and Baidu (BIDU).

Fund Details

Issuer
Kelly Strategic Management
Fund Name
Kelly CRISPR & Gene Editing Technology ETF
Tax Classification
Regulated Investment Company
Stock Exchange
NASDAQ
Current Symbol
NASDAQ:XDNA
Inception Date
1/12/2022
Fund Manager
Dustin Lewellyn, Ernesto Tong, Anand Desai
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
Strategic CRISPR & Gene Editing Technology Index
Category
Strategy
Focus
Theme
Development Level
Developed Markets
Region
Global
Number of Holdings
2

Fund Statistics

Assets Under Management
$2.58 million
Average Daily Volume
$0.00
Discount/Premium
0.00%

Administrator, Advisor and Custodian

Administrator
U.S. Bancorp Fund Services, LLC
Advisor
Kelly Strategic Management, LLC
Custodian
U.S. Bank, N.A.
Distributor
Foreside Fund Services, LLC
Transfer Agent
U.S. Bancorp Fund Services, LLC
Trustee
N/A
Lead Market Maker
Jane Street

Miscellaneous

Beta
0.92
Creation Unit
25,000
Creation Fee
$250.00
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Top 3 XDNA Holdings

  • First American Government Obligations Fund
    Holding Weight: 49.96%
  • First American Treasury Obligations Fund
    Holding Weight: 49.96%
  • DEPOSITS WITH BROKER FOR SHORT POSITIONS
    Holding Weight: 0.09%

This page (NASDAQ:XDNA) was last updated on 8/19/2025 by MarketBeat.com Staff
From Our Partners